title: Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
authors.forename: C Kent
authors.initials: CK
authors.lastname: Osborne
authors.forename: Andrew
authors.initials: A
authors.lastname: Evens
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D000077341:Lapatinib; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D000069283:Rituximab; D000068878:Trastuzumab; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001761:Bleomycin; D003520:Cyclophosphamide; D003606:Dacarbazine; D004317:Doxorubicin; D000077341:Lapatinib; D011241:Prednisone; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000069283:Rituximab; D000068878:Trastuzumab; D014747:Vinblastine; D014750:Vincristine; C485206:pertuzumab